Catalyst Pharmaceutical Partners, a pharmaceutical company developing prescription drugs to treat addiction, announced that it now plans to offer 3.35 million shares at $6. The company originally planned to offer 3 million shares at a range of $11-$13. First Albany Capital is managing the deal which is now expected to price this week.
